OCT 02, 2018 07:22 PM PDT

Mycobacterial Lung Disease, FDA Approves New Drug

WRITTEN BY: Nouran Amin

Image via National Heart, Lung, and Blood Institute - NIH

New drug seeking to treat antibiotic-resistant lung disease has just been approved by the U.S. Food and Drug Administration. The drug is called ‘Arikayce’ which stands for amikacin liposome inhalation suspension. Arikayce will specifically treat lung disease in a limited population of patients infected by a group of bacteria known as Mycobacterium avium complex (MAC) and who do not respond to conventional treatment.

MAC is a nontuberculous mycobacterium (NTM) that is mostly present in water and soil. Some of the symptoms of patients infected with MAC include persistent cough, fatigue, weight loss, night sweats, and occasionally shortness of breath and coughing up of blood.

"As bacteria continue to grow impervious to currently available antibiotics, we need to encourage the development of drugs that can treat resistant infections. That means utilizing novel tools intended to streamline development and encourage investment into these important endeavors," explains FDA Commissioner Scott Gottlieb, M.D. "This approval is the first time a drug is being approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, and it marks an important policy milestone. This pathway, advanced by Congress, aims to spur development of drugs targeting infections that lack effective therapies. We’re seeing a lot of early interest among sponsors in using this new pathway, and it’s our hope that it’ll spur more development and approval of antibacterial drugs for treating serious or life-threatening infections in limited populations of patients with unmet medical needs."

After successfully passing clinical trials, Arikayce is the first drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, or LPAD pathway. Arikayce will be delivered as an inhaled treatment through a nebulizer. There are some side effects noted in the clinical studies from taking the drug which include dysphonia (difficulty speaking), cough, ototoxicity (damaged hearing), upper airway irritation, musculoskeletal pain, fatigue, diarrhea and nausea. Additionally, the prescribing information includes warnings regarding the increased risk of respiratory implications that in some cases lead to hospitalization. These conditions include the increased risk of hypersensitivity pneumonitis (inflamed lungs), bronchospasm (tightening of the airway), exacerbation of underlying lung disease and hemoptysis (spitting up blood).

Learn more about Mycobacterial Lung Infection:

The FDA granted approval of Arikayce to Insmed, Inc. of Bridgewater, NJ.

Source: FDA

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Injectable Hydrogel Found Safe for Heart Repair
The first successful in-human clinical trial of an injectable hydrogel that aims to repair heart damage and restore cardiac function was recently conducted...
NOV 13, 2019
Technology
NOV 13, 2019
Biomagents for Drug Discovery
Scientists have recently developed a chip-like device that utilizes tiny magnets that sort large populations of mixed cell types. "We casually agreed...
NOV 13, 2019
Infographics
NOV 13, 2019
Surface Plasmon Resonance (SPR) Technology
Surface plasmon resonance (SPR) allows researchers to investigate different types of biomolecular interactions and mechanisms in real-time and label-free....
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Tailor-made Drug for Girl with Rare Genetic Disease
Researchers have used personalized medicine to develop a tailor-made genetic treatment for a girl diagnosed with a rare genetic disease known as Batten dis...
NOV 13, 2019
Health & Medicine
NOV 13, 2019
All you need to know about Orphan Drugs
Orphan drugs are medicinal products intended for the diagnosis, prevention, or treatment of very rare life-threatening diseases. To offset the high development cost of orphan drugs, in 1983,...
Loading Comments...